{
  "id": "54df69af1388e8454a000005",
  "type": "list",
  "question": "Which drugs are included in the FEC-75 regimen?",
  "ideal_answer": "Fluorouracil, epirubicin, and cyclophosphamide are included in the FEC-75 regimen. This chemotherapy regiment is used for breast cancer treatment.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/12525522",
    "http://www.ncbi.nlm.nih.gov/pubmed/16315865",
    "http://www.ncbi.nlm.nih.gov/pubmed/16282727",
    "http://www.ncbi.nlm.nih.gov/pubmed/18344024",
    "http://www.ncbi.nlm.nih.gov/pubmed/1988577",
    "http://www.ncbi.nlm.nih.gov/pubmed/10885599",
    "http://www.ncbi.nlm.nih.gov/pubmed/22902450",
    "http://www.ncbi.nlm.nih.gov/pubmed/11875727",
    "http://www.ncbi.nlm.nih.gov/pubmed/18189160",
    "http://www.ncbi.nlm.nih.gov/pubmed/24239210",
    "http://www.ncbi.nlm.nih.gov/pubmed/22772380",
    "http://www.ncbi.nlm.nih.gov/pubmed/7693420",
    "http://www.ncbi.nlm.nih.gov/pubmed/17647266",
    "http://www.ncbi.nlm.nih.gov/pubmed/17054108",
    "http://www.ncbi.nlm.nih.gov/pubmed/10963640",
    "http://www.ncbi.nlm.nih.gov/pubmed/8808724"
  ],
  "snippets": [
    {
      "text": "Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24239210",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Patients randomly assigned to sequential treatment received fluorouracil 500 mg/m(2), epirubicin 75 mg/m(2), and cyclophosphamide 500 mg/m(2) (FEC-75) on day 1 of a 21-day cycle for four cycles followed by paclitaxel 80 mg/m(2) and trastuzumab 2 mg/kg (after a 4 mg/kg loading dose) once per week for 12 weeks, while those randomly assigned to the concurrent treatment group received paclitaxel and trastuzumab once per week for 12 weeks followed by four cycles of FEC-75 (on day 1 of each 21-day cycle) and once-weekly trastuzumab, in the same doses as the sequential group.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24239210",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In May 2008, the patient underwent preoperative chemotherapy consisting of 4 courses of FEC 75(fluororracil, epirubicin, and cyclophosphamide).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22902450",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Stage II-IIIC HER2-positive breast cancer patients, including inflammatory disease, were treated with weekly-trastuzumab for 24 weeks administered concurrently with all primary chemotherapy containing paclitaxel (80 mg/m(2)) for 12 weeks and 4 cycles of FEC-75 (fluorouracil 500 mg/m(2), epirubicine 75 mg/m(2), and cyclophosphamide 500 mg/m(2)) followed by surgery. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22772380",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Further improvements can be achieved with dose-dense regimens, but densification of fluorouracil/epirubicin/cyclophosphamide (FEC) has proved difficult, with FEC(60) providing little benefit over standard chemotherapy and FEC(100) associated with toxicity. We investigated the feasibility of two intermediate dose-dense FEC regimens. Patients were randomised to six cycles of FEC(75) or FEC(90), with all three drugs given on day 1 of each 14-day cycle. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189160",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: A previously published prospective randomized phase 3 trial showed that administration of 24 weeks of primary systemic chemotherapy (PST) with paclitaxel and FEC(75) (fluorouracil, epirubicin, cyclophosphamide) concurrently with trastuzumab in patients with HER2-positive primary breast cancer resulted in a 60% pathologic complete response rate (PCR) with no associated severe cardiac toxicity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17647266",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Maintenance chemotherapy was FEC 75 (fluorouracil 500 mg/m(2), epirubicin 75 mg/m(2), and cyclophosphamide 500 mg/m(2) on Day 1 every 21 days for 4 cycles). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17054108",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The French Epirubicin Study Group carried out a randomized trial comparing epirubicin alone 75 mg/m2 with fluorouracil (5FU) 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 50 mg/m2 (FEC 50) and 5FU 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 75 mg/m2 (FEC 75) as first treatment for advanced breast cancer patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/1988577",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patients were randomised to 1 of 3 treatment groups: Group A (n = 207) received FEC 50 (fluorouracil 500 mg/m2, epirubicin 50 mg/m2 plus cyclophosphamide 500 mg/m2) every 21 days for 6 cycles; Group B (n = 193) received FEC 50 every 21 days for 3 cycles; Group C (n = 195) received FEC 75 (fluorouracil 500 mg/m2, epirubicin 75 mg/m2 plus cyclophosphamide 500 mg/m2) every 21 days for 3 cycles.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7693420",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sixty chemotherapy-naive breast cancer patients of 30 to 71 years in age, P.S. = 0-1, receiving 5-fluorouracil-epirubicin-cyclophosphamide (FEC 75) q 21 days or cyclophosphamide-methotrexate-5-fluorouracil (CMF) or 120 mg/m2 epirubicin or high dose mitomycin-methotrexate-mitoxantrone (MMM) q 14 days (+ G-CSF) or 100 mg/m2 epirubicin (+ G-CSF) were randomized to receive, 15 min before chemotherapy, 8 mg i.v. bolus of ondansetron or 3 mg i.v. granisetron or 5 mg i.v. tropisetron and no further antiemetic therapy in the following days.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8808724",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PATIENTS AND METHODS: Four hundred seventeen anthracycline-naive MBC patients were randomized to receive one of the following regimens: arm A: 11 cycles of fluorouracil 500 mg/m(2), epirubicin 75 mg/m(2), and cyclophosphamide 500 mg/m(2) (FEC 75) every 21 days; arm B: four cycles of FEC 100 (same regimen but with epirubicin 100 mg/m(2)) then eight cycles of FEC 50 (epirubicin 50 mg/m(2)); and arm C: four cycles of FEC 100 then restart the same regimen at disease progression in case of prior response or stabilization.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10963640",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The aim of this study, using a Fleming single-stage design, was to explore the efficacy and safety of Taxotere 100 x mg x m(-2) docetaxel and FEC 75 cyclophosphamide 500 mg x m(-2), fluorouracil 500 x mg x m(-2) and epirubicin 75 mg x m(-2), in alternating and sequential schedules for the first-line treatment of metastatic breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11875727",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PATIENTS AND METHODS: Between 1986 and 1990, 621 patients with operable breast cancer were randomly assigned to receive fluorouracil (Roche SA, Basel, Switzerland) 500 mg/m2, epirubicin (Pharmacia SA, Milan, Italy) 50 mg/m2, and cyclophosphamide (Asta Medica AG, Frankfurt, Germany) 500 mg/m2 every 21 days (FEC 50) for six cycles (6 FEC 50); FEC 50 for three cycles (3 FEC 50); or the same regimen with epirubicin 75 mg/m2 (FEC 75) for three cycles (3 FEC 75).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12525522",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We studied the feasibility of FEC (75) (fluorouracil: 500 mg/m(2), epirubicin: 75 mg/m(2), and cyclophosphamide:500 mg/m(2), q 3 w, 6 cycles) as adjuvant chemotherapy for 59 primary breast cancer patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16282727",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Between 1986 and 1990, 621 patients with operable breast cancer were randomly assigned to receive fluorouracil (Roche SA, Basel, Switzerland) 500 mg/m2, epirubicin (Pharmacia SA, Milan, Italy) 50 mg/m2, and cyclophosphamide (Asta Medica AG, Frankfurt, Germany) 500 mg/m2 every 21 days (FEC 50) for six cycles (6 FEC 50); FEC 50 for three cycles (3 FEC 50); or the same regimen with epirubicin 75 mg/m2 (FEC 75) for three cycles (3 FEC 75)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12525522",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Four hundred seventeen anthracycline-naive MBC patients were randomized to receive one of the following regimens: arm A: 11 cycles of fluorouracil 500 mg/m(2), epirubicin 75 mg/m(2), and cyclophosphamide 500 mg/m(2) (FEC 75) every 21 days; arm B: four cycles of FEC 100 (same regimen but with epirubicin 100 mg/m(2)) then eight cycles of FEC 50 (epirubicin 50 mg/m(2)); and arm C: four cycles of FEC 100 then restart the same regimen at disease progression in case of prior response or stabilization.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10963640",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The French Epirubicin Study Group carried out a randomized trial comparing epirubicin alone 75 mg/m2 with fluorouracil (5FU) 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 50 mg/m2 (FEC 50) and 5FU 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 75 mg/m2 (FEC 75) as first treatment for advanced breast cancer patients",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/1988577",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "fluorouracil, epirubicin, cyclophosphamide"
}